Azitra (AZTR) Retained Earnings (2022 - 2026)
Azitra's (AZTR) quarterly Retained Earnings came in at $82.9 million in Q1 2026, up 236.84% YoY from $24.6 million in Q1 2025, and up 221.02% on a QoQ basis from -$68.5 million in Q4 2025.
Azitra (AZTR) Retained Earnings (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Retained Earnings data on file, last reported at $82.9 million in Q1 2026.
- Quarterly Retained Earnings rose 236.84% year-over-year to $82.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.9 million (up 236.84% YoY) and the FY2025 annual result came in at -$68.5 million, down 208.31% from the prior year.
- Retained Earnings advanced to $82.9 million in Q1 2026, from -$68.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $82.9 million in Q1 2026 to a low of -$68.5 million in Q4 2025.
- A 5-year average of -$13.0 million and a median of -$46.1 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings tumbled 4710.13% — and 2026, when it soared 236.84%.
- Tracing AZTR's Retained Earnings over 5 years: stood at $1.1 million in 2022, then plunged by 4710.13% to -$48.6 million in 2023, then soared by 230.18% to $63.3 million in 2024, then plunged by 208.31% to -$68.5 million in 2025, then jumped by 221.02% to $82.9 million in 2026.
- The last three Retained Earnings figures came in at $82.9 million (Q1 2026), -$68.5 million (Q4 2025), and $68.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Azitra | 2.44 Mn | 2.44 Mn | - | 83.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.12 Mn |
| Mar 31, 2026 | 82.93 Mn |
| Dec 31, 2025 | -68.52 Mn |
| Sep 30, 2025 | 68.57 Mn |
| Jun 30, 2025 | -63.50 Mn |
| Mar 31, 2025 | -60.60 Mn |
| Dec 31, 2024 | 63.26 Mn |
| Sep 30, 2024 | -55.17 Mn |
| Jun 30, 2024 | -54.16 Mn |
| Mar 31, 2024 | 55.85 Mn |
| Dec 31, 2023 | -48.60 Mn |
| Sep 30, 2023 | -46.14 Mn |
| Jun 30, 2023 | -44.20 Mn |
| Dec 31, 2022 | 1.05 Mn |